Merck & Co provides C$4 million for Pan-Canadian life sciences research innovation sector

23 April 2013

Merck Canada, a unit of US pharma giant Merck & Co (NYSE: MRK) has announced that it is reinforcing its commitment to the Canadian life sciences research innovation sector, and will provide C$4 million ($3.9 million) in funding to the Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centers of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.

The IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in health care. All three CECR institutions - identified as CECR in 2008 by the federal government - share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.

Part of new R&D approach

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK